Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/38837| Title: | PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment | Authors: | Thouvenin, J. Van Marcke, C. Decoster, L. Raicevic, G. Punie, K. Vandenbulcke, M. Salgado, R. Van Valckenborgh, E. Maes, B. Joris, S. Vander Steichel, D. Vranken, K. Jacobs , S. Dedeurwaerdere, F. Martens, G. Devos, H. Duhoux, F. P. Rasschaert, M. Pauwels , P. Geboes, K. Collignon, J. Tejpar, S. Canon, J-L Peeters, M. Rutten, A. Van de Mooter, T. Vermeij, J. Schrijvers, D. Demey, W. Lybaert, W. Van Huysse, J. MEBIS, Jeroen Awada, A. Claes, K. B. M. Hebrant, A. Van der Meulen, J. Delafontaine, B. Vanden Bempt, I Maetens, J. de Hemptinne, M. Rottey, S. Aftimos, P. De Greve, J. |
Issue Date: | 2022 | Publisher: | ELSEVIER | Source: | ESMO Open, 7 (4) | Abstract: | PRECISION is an initiative from the Belgian Society of Medical Oncology (BSMO) in collaboration with several stakeholders, encompassing four programs that aim to boost genomic and clinical knowledge with the ultimate goal to offer patients with metastatic solid tumors molecularly guided treatments. The PRECISION 1 study has led to the creation of a clinico-genomic database. The Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) and GeNeo studies will increase the number of patients with advanced cancer that have comprehensive genotyping of their cancer. The PRECISION 2 project consists of investigator-initiated phase II studies aiming to provide access to a targeted drug for patients whose tumors harbor actionable mutations in case the matched drug is not available through reimbursement or clinical trials in Belgium. | Notes: | De Greve, J (corresponding author), Vrije Univ Brussel, UZBrussel, Dept Med Genet, Laarbeeklaan 101, B-1090 Jette, Belgium. Jacques.degreve@uzbrussel.be |
Keywords: | next-generation sequencing (NGS);metastatic tumors;genomic alterations genomic-driven therapy;genomic-driven therapy;molecular tumor board | Document URI: | http://hdl.handle.net/1942/38837 | e-ISSN: | 2059-7029 | DOI: | 10.1016/j.esmoop.2022.100524 | ISI #: | 000861050700001 | Rights: | 2022 Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | Category: | A1 | Type: | Journal Contribution |
| Appears in Collections: | Research publications |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| PRECISION_ the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment.pdf | Published version | 822.84 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.